NEWS

August 24, 2017

Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients

August 15, 2017

Portola Pharmaceuticals Announces AndexXa® (Andexanet Alfa) Biologics License Application Resubmission Accepted for Review by U.S. FDA

August 4, 2017

Johnson & Johnson Vision Announces Agreement to Acquire TearScience

May 18, 2017

Shire’s Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

May 16, 2017

Coherus BioSciences Prevails in ‘135 IPR Decision

May 11, 2017

Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners

May 10, 2017

Julie McHugh Joins HealthCare Royalty Partners Strategic Advisory Board

February 20, 2017

Smaller finance firms rise to fill gaps in Stamford

February 3, 2017

Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa

January 27, 2017

HealthCare Royalty Partners Announces New Chief Medical Officer, Senior-Level Promotions, and Further Regional Expansion